SCHEMBL1358649

SCHEMBL1358649

COc1ccc(N2CCCCC2=O)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.60
HTT P42858 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HRH3 Q9Y5N1 4/20 0.53
HRH1 P35367 1/20 0.48
AKR1C3 P42330 3/20 0.48
CHRNB2 P17787 3/20 0.48
CHRNA4 P43681 3/20 0.48
DPP4 P27487 1/20 0.44
DPP8 Q6V1X1 1/20 0.44
ALDH1A1 P00352 1/20 0.42
F2 P00734 3/20 0.42
F10 P00742 3/20 0.42
SLC29A1 Q99808 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRL1 P41146 1/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
BRD9 Q9H8M2 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741499 0.95 SMN1; SMN2 (0.65) NPC1HTTSMN1; SMN2HRH3HRH1
SCHEMBL255160 0.80 AKR1C3 (0.51) NPC1SMN1; SMN2HRH3AKR1C3ALDH1A1
Hydrochloric Acid SCHEMBL5650408 0.79 L3MBTL1 (0.48) NPC1HTTSMN1; SMN2CHRNB2CHRNA4
SCHEMBL15491817 0.79 AKR1C3 (0.50) NPC1SMN1; SMN2HRH3AKR1C3ALDH1A1
SCHEMBL8356124 0.79 AKR1C3 (0.50) NPC1SMN1; SMN2HRH3AKR1C3ALDH1A1
SCHEMBL2343208 0.78 AKR1C3 (0.49) HRH3HRH1AKR1C3ALDH1A1BRD9
SCHEMBL3593687 0.78 NTRK1 (0.52) NPC1HTTSMN1; SMN2CHRNB2CHRNA4
SCHEMBL3593684 0.77 NPC1 (0.44) NPC1HTTSMN1; SMN2HRH3CHRNB2
SCHEMBL3594508 0.77 CHRNB2 (0.56) NPC1HTTSMN1; SMN2CHRNB2CHRNA4
SCHEMBL12279805 0.77 AKR1C3 (0.50) NPC1SMN1; SMN2HRH3HRH1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067457-B2 Compounds useful as antagonists of CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20090197884-A1 Compounds Useful as Antagonists of CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197884-A1 Compounds Useful as Antagonists of CCR2 CCR2, CCR1, CXCR3 NPC1 712/4885HTT 3072/4885SMN1; SMN2 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.